Promoters and serotypes:: targeting of adeno-associated virus vectors for gene transfer in the rat central nervous system in vitro and in vivo

被引:158
作者
Shevtsova, Z [1 ]
Malik, JMI [1 ]
Michel, U [1 ]
Bähr, M [1 ]
Kügler, S [1 ]
机构
[1] Univ Gottingen, Sch Med, Dept Neurol, Vector Lab, D-37073 Gottingen, Germany
关键词
D O I
10.1113/expphysiol.2004.028159
中图分类号
Q4 [生理学];
学科分类号
071003 ;
摘要
The brain parenchyma consists of several different cell types, such as neurones, astrocytes, microglia, oligodendroglia and epithelial cells, which are morphologically and functionally intermingled in highly complex three-dimensional structures. These different cell types are also present in cultures of brain cells prepared to serve as model systems of CNS physiology. Gene transfer, either in a therapeutic attempt or in basic research, is a fascinating and promising tool to manipulate both the complex physiology of the brain and that of isolated neuronal cells. Viral vectors based on the parvovirus, adeno-associated virus (AAV), have emerged as powerful transgene delivery vehicles. Here we describe highly efficient targeting of AAV vectors to either neurones or astrocytes in cultured primary brain cell cultures. We also show that transcriptional targeting can be achieved by the use of small promoters, significantly boosting the transgene capacity of the recombinantviral genome. However, we also demonstrate that successful targeting of a vector in vitro does not necessarily imply that the same targeting works in the adult brain. Cross-packaging the AAV-2 genome in capsids of other serotypes adds additional benefits to this vector system. In the brain, the serotype-5 capsid allows for drastically increased spread of the recombinant vector as compared to the serotype-2 capsid. Finally, we emphasize the optimal targeting approach, in which the natural tropism of a vector for a specific cell type is employed. Taken together, these data demonstrate the flexibility which AAV-based vector systems offer in physiological research.
引用
收藏
页码:53 / 59
页数:7
相关论文
共 26 条
[1]   Comparison of the human versus murine cytomegalovirus immediate early gene promoters for transgene expression by adenoviral vectors [J].
Addison, CL ;
Hitt, M ;
Kunsken, D ;
Graham, FL .
JOURNAL OF GENERAL VIROLOGY, 1997, 78 :1653-1661
[2]   TrkB gene transfer protects retinal ganglion cells from axotomy-induced death in vivo [J].
Cheng, L ;
Sapieha, P ;
Kittlerová, P ;
Hauswirth, WW ;
Di Polo, A .
JOURNAL OF NEUROSCIENCE, 2002, 22 (10) :3977-3986
[3]   Recombinant adeno-associated virus type 2, 4, and 5 vectors: Transduction of variant cell types and regions in the mammalian central nervous system [J].
Davidson, BL ;
Stein, CS ;
Heth, JA ;
Martins, I ;
Kotin, RM ;
Derksen, TA ;
Zabner, J ;
Ghodsi, A ;
Chiorini, JA .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (07) :3428-3432
[4]   Identification of PDGFR as a receptor for AAV-5 transduction [J].
Di Pasquale, G ;
Davidson, BL ;
Stein, CS ;
Martins, IS ;
Scudiero, D ;
Monks, A ;
Chiorini, JA .
NATURE MEDICINE, 2003, 9 (10) :1306-1312
[5]   Counteracting the Nogo receptor enhances optic nerve regeneration if retinal ganglion cells are in an active growth state [J].
Fischer, D ;
He, ZG ;
Benowitz, LI .
JOURNAL OF NEUROSCIENCE, 2004, 24 (07) :1646-1651
[6]   Promoters and regulatory elements that improve adeno-associated virus transgene expression in the brain [J].
Fitzsimons, HL ;
Bland, RJ ;
During, MJ .
METHODS, 2002, 28 (02) :227-236
[7]   Gene therapy progress and prospects: Recombinant adeno-associated virus (rAAV) vectors [J].
Flotte, TR .
GENE THERAPY, 2004, 11 (10) :805-810
[8]   Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy [J].
Gao, GP ;
Alvira, MR ;
Wang, LL ;
Calcedo, R ;
Johnston, J ;
Wilson, JM .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2002, 99 (18) :11854-11859
[9]   Adenoviral-mediated, high-level, cell-specific transgene expression:: A SYN1-WPRE cassette mediates increased transgene expression with no loss of neuron specificity [J].
Glover, CPJ ;
Bienemann, AS ;
Heywood, DJ ;
Cosgrave, AS ;
Uney, JB .
MOLECULAR THERAPY, 2002, 5 (05) :509-516
[10]   Helper virus-free, optically controllable, and two-plasmid-based production of adeno-associated virus vectors of serotypes 1 to 6 [J].
Grimm, D ;
Kay, MA ;
Kleinschmidt, JA .
MOLECULAR THERAPY, 2003, 7 (06) :839-850